REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1593793
Multiple signaling pathways in the frontiers of Lung cancer progression
Provisionally accepted
- 1Jishou University, Jishou, China
- 2Zhuzhou Central Hospital, Zhuzhou, Hunan, China
- 3Hunan Traditional Chinese Medical College, Zhuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Lung cancer is a prevalent malignant tumor and the leading cause of cancer-related mortality worldwide. LC is a complex respiratory condition that poses significant challenges for both clinicians and researchers. Crucially, dysregulation of molecular signaling pathways is a key message point in LC. Numerous reviews have highlighted effective treatments for LC by targeting disrupted signaling pathways. Understanding the roles and interconnections of various signaling pathways in LC is crucial. Therefore, this paper reviews the pathogenesis, biological functions and their important interactions in lung cancer. Frist, we reviewed relevant signaling pathways involved in LC, including Wnt, PI3K/Akt, Notch, PD-1/PD-L1, NF-κB, Hippo, MAPK, Hedgehog, AMPK. Immediately thereafter, we further explored the biological functions of LC in this area of pathophysiology, such as apoptosis, metastasis and proliferation. In conclusion, after our deeper understanding of the interactions of these signaling pathways in LC. And we must recognize that the interactions between the above signaling pathways can lead to comprehensive as well as novel therapeutic approaches for LC.
Keywords: Signal Transduction, lung cancer, therapeutic targets, oncogene, metastasis
Received: 14 Mar 2025; Accepted: 26 May 2025.
Copyright: © 2025 Liu, Zhou, Ou, Chen, Long, Ting, Li and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yingzheng Tan, Zhuzhou Central Hospital, Zhuzhou, Hunan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.